Regeneron Says Its Antibody Cocktail Reduces The Risk of Covid By More Than 80% For At Least EIGHT MONTHS

The Daily Mail

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

Regeneron Pharmaceuticals Inc announced on Monday that its antibody cocktail can severely slash the risk of being infected with COVID-19 for up to eight months.

The combo therapy, REGEN-COV, was approved in November 2020 for emergency use to treat people with mild-to-moderate COVID-19 cases in the U.S.

But the U.S. Food and Drug Administration (FDA) expanded authorization in July 2021 so the drug can also be used as a preventive treatment.

Late-stage trial data showed a single dose can lower the risk of contracting Covid by 81.6 percent between two and six-months after the cocktail is administered.

The FDA has previously stated that REGEN-COV is not a replacement for vaccination, but rather can be used in conjunction with people who develop a weak immune response to the shots.